載入...
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
BACKGROUND: No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC. Patients and methods: MITO2 is a randomised multice...
Na minha lista:
發表在: | Oncotarget |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
格式: | Artigo |
語言: | Inglês |
出版: |
Impact Journals LLC
2016
|
主題: | |
在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5341934/ https://ncbi.nlm.nih.gov/pubmed/27655643 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12056 |
標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|